Evmann Holding Sets Sights on Expanding Ophthalmology Investments at ESCRS

Evmann Investments Holding BV is taking a proactive approach to strengthening its investment footprint in the ophthalmology sector. The Netherlands-based holding company, with operations spanning over 93 countries via its German subsidiary VSY Biotechnology GmbH, is setting a new course for growth within the healthcare arena.

At the forefront of this strategic expansion is Dr. Ercan Varlibas, Chairman of the Board of Evmann Investments Holding. Dr. Varlibas took advantage of the European Society of Cataract and Refractive Surgeons (ESCRS) Winter Meeting in Frankfurt, Germany, from February 15-18, 2024, to engage in key discussions that are expected to propel the company’s investment endeavors forward. A highlight of the meeting was Dr. Varlibas' interaction with Dr. Filomena Ribeiro, the newly appointed President of the ESCRS.

Dr. Varlibas expressed his optimism about the company's direction, stating, "Evmann Investments Holding is actively pursuing new investment opportunities, with a keen interest in the healthcare sector, particularly ophthalmology. Our commitment is to leverage our resources for significant future investments in this area. As Germany's second-largest legal manufacturer in the ophthalmology sector, VSY Biotechnology is pivotal to Evmann Holding's strategy in driving advancements in medical science and enhancing patient care."

This statement not only highlights Evmann Holding's dedication to advancing healthcare but also emphasizes the strategic importance of VSY Biotechnology in achieving the company’s goals. By focusing on ophthalmology, Evmann Holding aims to contribute to the development of medical science and improve patient outcomes.